Hennion & Walsh Asset Management, Inc. Global Blood Therapeutics, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$32.4 - $68.18 $34,603 - $72,816	1,068 Added 0.87%	124,483 $8.48 Million
Q2 2022 Jul 19, 2022	SELL	$22.3 - $37.39 $176,972 - $296,727	-7,936 Reduced 6.04%	123,415 $3.94 Million
Q1 2022 Apr 26, 2022	BUY	$25.68 - $35.59 $266,686 - $369,602	10,385 Added 8.59%	131,351 $4.55 Million
Q4 2021 Feb 14, 2022	SELL	$24.9 - $40.26 $151,367 - $244,740	-6,079 Reduced 4.78%	120,966 $3.54 Million
Q3 2021 Nov 12, 2021	BUY	$25.48 - $37.34 $147,478 - $216,123	5,788 Added 4.77%	127,045 $3.24 Million
Q2 2021 Aug 13, 2021	BUY	$32.46 - $43.42 $247,572 - $331,164	7,627 Added 6.71%	121,257 $4.25 Million
Q1 2021 May 17, 2021	BUY	$38.94 - $50.85 $4.42 Million - $5.78 Million	113,630 New	113,630 $4.63 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.